Neos Therapeutics Incorporated (NASDAQ:NEOS) on Focus After Report of More Shorts

July 18, 2017 - By Ellis Scott

 Neos Therapeutics Incorporated (NASDAQ:NEOS) on Focus After Report of More Shorts

The stock of Neos Therapeutics Incorporated (NASDAQ:NEOS) registered an increase of 2.57% in short interest. NEOS’s total short interest was 2.87 million shares in July as published by FINRA. Its up 2.57% from 2.80M shares, reported previously. With 314,900 shares average volume, it will take short sellers 9 days to cover their NEOS’s short positions. The short interest to Neos Therapeutics Incorporated’s float is 24.16%.

The stock decreased 0.71% or $0.05 during the last trading session, reaching $7. About shares traded. Neos Therapeutics Inc (NASDAQ:NEOS) has risen 9.07% since July 18, 2016 and is uptrending. It has underperformed by 7.63% the S&P500.

Neos Therapeutics, Inc. is a pharmaceutical company. The company has market cap of $197.12 million. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. It currently has negative earnings. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals.

Neos Therapeutics Inc (NASDAQ:NEOS) Ratings Coverage

Among 6 analysts covering Neos Therapeutics (NASDAQ:NEOS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Neos Therapeutics had 11 analyst reports since August 17, 2015 according to SRatingsIntel. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Market Outperform” rating given on Monday, August 17 by JMP Securities. RBC Capital Markets initiated Neos Therapeutics Inc (NASDAQ:NEOS) on Monday, August 17 with “Outperform” rating. BMO Capital Markets initiated Neos Therapeutics Inc (NASDAQ:NEOS) on Wednesday, June 29 with “Outperform” rating. On Monday, August 17 the stock rating was initiated by BMO Capital Markets with “Outperform”. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) earned “Outperform” rating by Wells Fargo on Friday, February 19. The company was downgraded on Monday, March 20 by UBS. The company was maintained on Thursday, November 12 by RBC Capital Markets. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, June 20.

More news for Neos Therapeutics Inc (NASDAQ:NEOS) were recently published by: Seekingalpha.com, which released: “Neos Looks Attractive With Short And Long-Term Catalysts” on June 30, 2017. Globenewswire.com‘s article titled: “Neos Therapeutics Announces FDA Approval of Cotempla XR-ODTâ„¢ (methylphenidate …” and published on June 20, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.